Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 12, Issue 1, 2003, Pages 87-100

  Drucker, Daniel J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diabetes; Drugs; Enzyme inhibitors; GIP; GLP 1; Glucagon like peptides; Glucose; Incretin; Inhibitor; Peptidase; Peptide

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; APROTININ; BETA CASOMORPHINE; BRADYKININ; DIPEPTIDYL PEPTIDASE IV; ENDOMORPHIN 2; ENTEROSTATIN; ENZYME INHIBITOR; EOTAXIN; GASTRIN RELEASING PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INSULIN; INTERLEUKIN 2; ISOLEUCINE; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; NEUROPEPTIDE Y; PHOSPHORUS 32; PROTEIN INHIBITOR; PYRROLIDINE DERIVATIVE; RANTES; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMAL CELL DERIVED FACTOR 1BETA; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE;

AMINO TERMINAL SEQUENCE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MOUSE; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA HALF LIFE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PRURITUS; RAT; REVIEW; TREATMENT PLANNING;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; HUMANS; SERINE PROTEINASE INHIBITORS;

EID: 0037234531     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.1.87     Document Type: Review

References (159)

1. VILSBOLL T, KRARUP T, DEACON CF, MADSBAD S, HOLST JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in Type 2 diabetic patients. Diabetes (2001) 50:609-613.
2. RASK E, OLSSON T, SODERBERG S et al.: Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care (2001) 24:1640-1645.
3. DUPRE J, ROSS SA,WATSON D, BROWN JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. (1973) 37:826-828.
4. MEIER JJ, NAUCK MA, SCHMIDT WE, GALLWITZ B: Gastric Inhibitory Polypeptide: the neglected incretin revisited. Regul. Pept. (2002) 107:1-13.
5. BAGGIO L, KIEFFER TJ, DRUCKER DJ: GLP-1 but not GIP regulates fasting and non-enteral glucose clearance in mice. Endocrinology (2000) 141:3703-3709.
6. LEWIS JT, DAYANANDAN B, HABENER JF, KIEFFER TJ: Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology (2000) 141:3710-3716.
7. MIYAWAKI K, YAMADA Y, YANO H et al.: Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA (1999) 96:14843-14847.
8. YIP RG, WOLFE MM: GIP biology and fat metabolism. Life Sci. (2000) 66:91-103.
9. MIYAWAKI K, YAMADA Y, BAN N et al.: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. (2002) 8:738-742.
10. LYNN FC, PAMIR N, NG EH, MCINTOSH CH, KIEFFER TJ, PEDERSON RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes (2001) 50:1004-1011.
11. JONES IR, OWENS DR, MOODY AJ, LUZIO SD, MORRIS T, HAYES TM: The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin- dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia (1987) 30:707-712.
12. NAUCK MA, HEIMESAAT MM, ORSKOV C, HOIST JJ, EBERT R, CREUTZFELDT W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. (1993) 91:301-307.
13. ELAHI D, MCALOON-DYKE M, FUKAGAWA NK et al.:The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. (1994) 51:63-74.
14. VILSBOLL T, KRARUP T, MADSBAD S, HOLST JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia (2002) 45:1111-1119.
15. MEIER JJ, HUCKING K, HOLST JJ, DEACON CF, SCHMIEGEL WH, NAUCK MA: Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes (2001) 50:2497-2504.
16. O'HARTE FP, GAULT VA, PARKER JC et al.: Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetogia (2002) 45:1281-1291.
17. LUGARI R, DEI CAS A, UGOLOTTI D et al.: Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human Type 2 (non insulin-dependent) diabetes. Horm. Metab. Res. (2002) 34:150-154.
18. RUIZ-GRANDE C, PINTADO J, ALARCON C, CASTILLA C, VALVERDE I, LOPEZ-NOVOA JM: Renal catabolism of human glucagon-like peptides 1 and 2. Can. J. Physiol. Pharmacol. (1990) 68:1568-1573.
19. RUIZ-GRANDE C, ALARCON C, ALCANTARA A et al.: Renal catabolism of truncated glucagon-like peptide 1. Horm. Metab. Res. (1993) 25:612-616.
20. MENTLEIN R, GALLWITZ B, SCHMIDT WE: Dipepridyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. (1993) 214:829-835.
21. KIEFFER TJ, MCINTOSH CH, PEDERSON RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 136:3585-3596.
22. DEACON CF, NAUCK MA, TOFT-NIELSEN M, PRIDAL L, WILLMS B, HOLST JJ: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes (1995) 44:1126-1131.
23. HUPE-SODMANN K, MCGREGOR GP, BRIDENBAUGH R et al: Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. (1995) 58:149-156.
24. DRUCKER DJ, PHILIPPE J, MOJSOV S, CHICK WL, HABENER JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA (1987) 84:3434-3438.
25. MOJSOV S, WEIR GC, HABENER JF: Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. (1987) 79:616-619.
26. ORSKOV C, HOLST JJ, NIELSEN OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology (1988) 123:2009-2013.
27. HOLZ GG, KUHTREIBER WM, HABENER JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature (1993) 361:362-365.
28. WANG Y, EGAN JM, RAYGADA M, NADIV O, ROTH J, MONTROSE-RAFIZADEH C: Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 104-638 cells. Endocrinology (1995) 136(11):4910-4917.
29. FEHMANN H-C, HABENER JF: Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 ca. Endocrinology (1992) 130:159-166.
30. WANG Y, PERFETTI R, GREIG NH et al.: Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. (1997) 99:2883-2889.
31. WILLMS B, WERNER J, HOIST JJ, ORSKOV C, CREUTZFELDT W, NAUCK MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36)amide in Type 2 (non-insulin dependent) diabetic patients. J. Clin. Endocrinol, Metab. (1996) 81:327-332.
32. NAUCK MA, NIEDEREICHHOLZ U, ETTLER R et al.: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. (1997) 273:E981-E988.
33. KAWAI K, SUZUKI S, OHASHI S, MUKAI H, MURAYMA Y, YAMASHITA K: Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs. Acta Endocrinol. (Copenh.) (1990) 123:661-667.
34. KASHIMA Y, MIKI T, SHIBASAKI T et al.: Critical role of cAMP-GEFII/Rim2 complex in incretin-potentiated insulin secretion. J. Biol. Chem. (2001) 276:46046-46053.
35. 2+-signaling pathway in pancreatic b-cells by the insulinotropic hormone glucagon-like peptide-1. J. Biol Chem. (1995) 270:17749-17757.
36. LIGHT PE, MANNING FOX JE, RIEDEL MJ, WHEELER MB: Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol. Endocrinol. (2002) 16:2135-2144.
37. EDVELL A, LINDSTROM P: Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology (1999) 140:778-783.
38. XU G, STOFFERS DA, HABENER JE, BONNER-WEIR S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 48:2270-2276.
39. STOFFERS DA, KIEFFER TJ, HUSSAIN MA et al.: Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes (2000) 49:741-748.
40. ZHOU J, WANG X, PINEYRO MA, EGAN JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes (1999) 48:2358-2366.
41. HUI H, WRIGHT C, PERFETTI R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes (2001) 50:785-796.
42. DRUCKER DJ: Glucagon-like peptides: Regulators of cell proliferation, differentiation and apoptosis. Mol. Endocrinol. (2003) 17 (In press).
43. BEAK SA, HEATH MM, SMALL CJ et al.: Glucagon-like peptide-1 stimulates luteinizing hormone releasing hormone secretion in a rodent hypothalamic neuronal cell line (GT1-7). J. Clin. Invest. (1998) 101:1334-1341.
44. BEAK SA, SMALL CJ, ILOVAISKAIA I et al.: Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology (1996) 137:4130-4138.
45. LARSEN PJ, TANG-CHRISTENSEN M, JESSOP DS: Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology (1997) 138:4445-4455.
46. TURTON MD, O'SHEA D, GUNN I et al.: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 379:69-72.
47. DONAHEY JCK, VAN DIJK G, WOODS SC, SEELEY RJ: Intraventricular GLP-1 reduces short- but not long-term food intake or bodyweight in lean and obese rats. Brain Res. (1998) 779:75-83.
48. YOUNG AA, GEDULIN BR, BHAVSAR S et al: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes (1999) 48:1026-1034.
49. LARSEN PJ, FLEDELIUS C, KNUDSEN LB, TANG-CHRISTENSEN M: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes (2001) 50:2530-2539.
50. VERDICH C, FLINT A, GUTZWILLER JP et al.: A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol, Metab. (2001) 86:4382-4389.
51. ZANDER M, MADSBAD S, MADSEN JL, HOLST JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in Type 2 diabetes: a parallel-group study. Lancet (2002) 359:824-830.
52. WANG Z, WANG RM, OWJI AA, SMITH DM, GHATEI MA, BLOOM SR. Glucagon-like peptide 1 is a physiological incretin in rat. J. Clin. Invest. (1995) 95:417-421.
53. KOLLIGS F, FEHMANN H-C, GOKE R, GOKE B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes (1995) 44:16-19.
54. EDWARDS CM, TODD JF, MAHMOUDI M et al.: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes (1999) 48:86-93.
55. SCHIRRA J, STURM K LEICHT P, ARNOLD R, GOKE B, KATSCHINSKI M: Exendin (9-39)amide is an antagonist of glucagon-like peptide-1(7- 36)amide in humans. J. Clin. Invest. (1998) 101:1421-1430.
56. SCROCCHI LA, BROWN TJ, MACLUSKY N et al.: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. (1996) 2:1254-1258.
57. MEERAN K, O'SHEA D, EDWARDS CM et al.: Repeated intracerebroventricular administration of glucagon-like pepride-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology (1999) 140:244-250.
58. SCROCCHI LA, DRUCKER DJ: Effects of aging and a high fat diet on body weight and glucose control in GLP-1R-/- mice. Endocrinology (1998) 139:3127-3132.
59. LING Z, WU D, ZAMBRE Y et al.: Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. (2001) 438:382-387.
60. SCROCCHI LA, HILL ME, SALEH J, PERKINS B, DRUCKER DJ: Elimination of GLP-1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes (2000) 49:1552-1560.
61. PEDERSON RA, SATKUNARAJAH M, MCINTOSH CH et al.: Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes (1998) 47:1046-1052.
62. GUTNIAK M, ORSKOV C, HOLST JJ, AHREN B, EFENDIC S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. (1992) 326:1316-1322.
63. EDWARDS CM, STANLEY SA, DAVIS R et al.: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol Metab. (2001) 281:E155-E161.
64. GUTNIAK MK, LINDE B, HOLST JJ, EFENDIC S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care (1994) 17:1039-1044.
65. RACHMAN J, GRIBBLE FM, BARROW BA, LEVY JC, BUCHANAN KD, TURNER RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36)amide in patients with NIDDM. Diabetes (1996) 45:1524-1530.
66. CREUTZFELD WO, KLEINE N, WILLMS B, ORSKOV C, HOLST JJ, NAUCK MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in Type I diabetic patients. Diabetes Care (1996) 19:580-586.
67. NATHAN DM, SCHREIBER E, FOGEL H, MOJSOV S, HABENER JF: Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and non-diabetic subjects. Diabetes Care (1992) 15:270-276.
68. GUTNIAK MK, JUNTTI-BERGGREN L, HELLSTROM PM, GUENIFI A, HOLST JJ, EFENDIC S: Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care (1996) 19:857-863.
69. DUPRE J, BEHME MT, HRAMIAK IM et al.: Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes (1995) 44:626-630.
70. DEACON CF, JOHNSEN AH, HOLST JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. (1995) 80:952-957.
71. ORSKOV C, WETTERGREN A, HOLST JJ: Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes (1993) 42:658-661.
72. LARSEN J, HYLLEBERG B, NG K, DAMSBO P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care (2001) 24:1416-1421.
73. DRUCKER DJ: Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr. Pharm. Des. (2001) 7:1399-1412.
74. RACHMAN J, BARROW BA, LEVY JC, TURNER RC: Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia (1997) 40:205-211.
75. TOFT-NIELSEN MB, MADSBAD S, HOLST JJ: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in Type 2 diabetic patients. Diabetes Care (1999) 22:1137-1143.
76. TODD JF, EDWARDS CM, GHATEI MA, MATHER HM, BLOOM SR. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes. Clin. Sci. (Colch.) (1998) 95:325-329.
77. GOKE R, FEHMANN H-C, LINN T et al.: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. (1993) 268:19650-19655.
78. EGAN JM, CLOCQUET AR, ELAHI D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to Type 2 diabetes. J. Clin. Endocrinol. Metab. (2002) 87:1282-1290.
79. AGERSO H, JENSEN LB, ELBROND B, ROLAN P, ZDRAVKOVIC M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia (2002) 45:195-202.
80. JUHL CB, HOLLINGDAL M, STURIS J: Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in Type 2 diabetes. Diabetes (2002) 51:424-429.
81. MENTLEIN R: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. (1999) 85:9-24.
82. GORRELL MD, GYSBERS V, MCCAUGHAN GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. (2001) 54:249-264.
83. IWAKI-EGAWA S, WATANABE Y, KIKUYA Y, FUJIMOTO Y: Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J. Biochem. (Tokyo) (1998) 124:428-433.
84. DURINX C, LAMBEIR AM, BOSMANS E et al.: Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. (2000) 267:5608-5613.
85. DAVID F, BERNARD AM, PIERRES M, MARGUET D: Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases.J. Biol. Chem (1993) 268:17247-17252.
86. ABBOTT CA, BAKER E, SUTHERLAND GR, MCCAUGHAN GW: Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics (1994) 40:331-338.
87. HONG WJ, PETELL JK, SWANK D, SANFORD J, HIXSON DC, DOYLE D: Expression of dipeptidyl peptidase IV in rat tissues is mainly regulated at the mRNA levels. Exp. Cell Res. (1989) 182:256-266.
88. SAKAMOTO J, WATANABE T, TERAMUKAI S et al.: Distribution of adenosine deaminase binding protein in normal and malignant tissues of the gastrointestinal tract studied by monoclonal antibodies. J. Surg. Oncol. (1993) 52:124-134.
89. MORIMOTO C, SCHLOSSMAN SF: The structure and function of CD26 in the T-cell immune response. Immunol. Rev. (1998) 161:55-70.
90. HILDEBRANDT M, REUTTER W, ARCK P, ROSE M, KLAPP BF: A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin. Sci. (Lond) (2000) 99:93-104.
91. OHTSUKI T, TSUDA H, MORIMOTO C: Good or evil: CD26 and HIV infection. J Dermatol. Sci. (2000) 22:152-160.
92. IWATA S, MORIMOTO C: CD26/dipeptidyl peptidase IV in context. The diflerent roles of a multifunctional ectoenzyme in malignant transformation. J. Exp. Med. (1999) 190:301-306.
93. DANG NH, MORIMOTO C: CD26: an expanding role in immune regulation and cancer. Histol. Histopathol. (2002) 17:1213-1226.
94. ISHII T, OHNUMA K, MURAKAMI A et al.: CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad Sci. USA (2001) 98:12138-12143.
95. BUHLING F, KUNZ D, REINHOLD D et al.: Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat. Immun. (1994) 13:270-279.
96. HEGEN M, KAMEOKA J, DONG RP, MORIMOTO C, SCHLOSSMAN SF: Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation. Adv. Exp. Med. Biol. (1997) 421:109-116.
97. HEGEN M, KAMEOKA J, DONG RP, SCHLOSSMAN SF, MORIMOTO C: Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology (1997) 90:257-264.
98. IKUSHIMA H, MUNAKATA Y, ISHII T et al.: Internalization of CD26 by mannose 6-phosphate/insulin-like growth Factor II receptor contributes to T cell activation. Proc. Natl. Acad. Sci. USA (2000) 97:8439-8444.
99. IKUSHIMA H, MUNAKATA Y, IWATA S et al.: Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth Factor II receptor. Cell Immunol. (2002) 215:106-110.
100. OHNUMA K, MUNAKATA Y, ISHII T et al.: Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J. Immunol. (2001) 167:6745-6755.
101. OHNUMA K, ISHII T, IWATA S et al.: G1/S cell cycle arrest provoked in human T cells by antibody to CD26. Immunology (2002) 107:325-333.
102. COBURN MC, HIXSON DC, REICHNER JS: In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV. Cell Immunol. (1994) 158:269-280.
103. MARGUET D, BAGGIO, L, KOBAYASHI T et al.: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA (2000) 97:6874-6879.
104. PERNER F, GYURIS T, RAKOCZY G et al.: Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence. J. Lab. Clin. Med. (1999) 134:56-67.
105. FIRNEISZ G, LAKATOS PL, SZALAY F: Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand. J. Gastroenterol. (2001) 36:877-880.
106. GOTOH H, HAGIHARA M, NAGATSU T, IWATA H, MIURA T: Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients. Clin. Chem. (1988) 34:2499-2501.
107. REINHOLD D, HEMMER B, GRAN B et al.: Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease. Adv. Exp. Med. Biol. (2000) 477:155-160.
108. VANHAM G, KESTENS L, DE MEESTER I et al.: Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J. Acquir. Immune Defic. Syndr. (1993) 6:749-757.
109. HOSONO O, HOMMA T, KOBAYASHI H et al.: Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Clin. Immunol. (1999) 91:283-295.
110. KEANE NM, PRICE P. LEE S, STONE SF, FRENCH MA. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of Type 2 and Type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin. Exp. Immunol. (2001) 126:111-116.
111. MENTLEIN R, STAVES R, RIXMATZEN H, TINNEBERG HR: Influence of pregnancy on dipeptidyl peptidase IV activity (CD 26 leukocyte differentiation antigen) of circulating lymphocytes. Eur. J. Clin. Chem. Clin. Biochem. (1991) 29:477-480.
112. ROSE M, HILDEBRANDT M, FLIEGE H, SEIBOLD S, MONNIKES H, KLAPP BF: T-cell immune parameters and depression in patients with Crohn's disease. J. Clin. Gastroenterol. (2002) 34:40-48.
113. MAES M, DE MEESTER I, VERKERK R et al.: Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: relationships with immune- inflammatory markers. Psychoneuroendocrinology (1997) 22:65-78.
114. ELGUN S, KESKINEGE A, KUMBASAR H: Dipeptidyl peptidase IV and adenosine deaminase activity. Decrease in depression. Psychoneuroendocrinology (1999) 24:823-832.
115. HILDEBRANDT M, ROSE M, MAYR C et al.: Dipeptidyl peptidase IV (DPP IV, CD26) in patients with mental eating disorders. Adv. Exp. Med. Biol. (2000) 477:197-204.
116. STANCIKOVA M, LOJDA Z, LUKAC J, RUZICKOVA M: Dipeptidyl peptidase IV in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. (1992) 10:381-385.
117. CORDERO OJ, SALGADO FJ, MERAVARELA A, NOGUEIRA M: Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol. Int. (2001) 21:69-74.
118. SCHONERMARCK U, CSERNOK E, TRABANDT A, HANSEN H, GROSS WL: Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin. Exp. Rheumatol. (2000) 18:457-463.
119. LEFEBVRE J, MURPHEY LJ, HARTERT TV, JIAO SHAN R, SIMMONS WH, BROWN NJ: Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension (2002) 39:460-464.
120. TANAKA T, UMEKI K, YAMAMOTO I, SAKAMOTO F, NOGUCHI S, OHTAKI S: CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Int. J. Cancer (1995) 64:326-331.
121. UMEKI K, TANAKA T, YAMAMOTO I et al.: Differential expression of dipeptidyl peptidase IV (CD26) and thyroid peroxidase in neoplastic thyroid tissues. Endocr. J. (1996) 43:53-60.
122. WILSON MJ, RUHLAND AR, QUAST BJ, REDDY PK, EWING SL, SINHA AA: Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J. Androl. (2000) 21:220-226.
123. CORDERO OJ, AYUDE D, NOGUEIRA M, RODRIGUEZ-BERROCAL FJ, DE LA CADENA MP: Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br. J. Cancer (2000) 83:1139-1146.
124. UEMATSU T, URADE M, YAMAOKA M, YOSHIOKA W: Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients. J. Oral Pathol. Med. (1996) 25:507-512.
125. LAMBEIR AM, PROOST P, DURINX C et al.: Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. (2001) 276:29839-29845.
126. LAMBEIR AM, DURINX C, PROOST P, VAN DAMME J, SCHARPE S, DE MEESTER I: Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. (2001) 507:327-330.
127. DE MEESTER I, DURINX C, BAL G et al.: Natural substrates of dipeptidyl peptidase IV. Adv. Exp. Med. Biol. (2000) 477:67-87.
128. POSPISILIK JA, HINKE SA, PEDERSON RA et al.: Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul. Pept. (2001) 6:133-141.
129. HINKE SA, POSPISILIK JA, DEMUTH HU et al.: Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J. Biol. Chem. (2000) 275:3827-3834.
130. POULSEN MD, HANSEN GH, DABELSTEEN E, HOYER PE, NOREN O, SJOSTROM H: Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells. J. Histochem. Cytochem. (1993) 41:81-88.
131. HANSEN L, DEACON CF, ORSKOV C, HOLST JJ: Glucagon-like pepride-1-(736)amide is transformed to glucagon-like pepride-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries Supplying the L cells of the porcine intestine. Endocrinology (1999) 140:5356-5363.
132. PAULY RP, DEMUTH HU, ROSCHE F et al.: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism (1999) 48:385-389.
133. BALKAN B, KWASNIK L, MISERENDINO R, HOLST JJ, LI X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42:1324-1331.
134. DEACON CF, WAMBERG S, BIE P, HUGHES TE, HOLST JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. (2002) 172:355-362.
135. REIMER MK, HOIST JJ, AHREN B et al.: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. (2002) 146:717-727.
136. NAGAKURA T, YASUDA N, YAMAZAKI K et al.: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. (2001) 284:501-506.
137. KNUDSEN LB, PRIDAL L: Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(736)amide after in vivo administration to dogs and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. (1996) 318:429-435.
138. AYTAC U, CLARET FX, HO L et al.: Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res. (2001) 61:7204-7210.
139. WESLEY UV, ALBINO AP, TIWARI S, HOUGHTON AN: A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J. Exp. Med. (1999) 190:311-322.
140. PETHIYAGODA CL, WELCH DR, FLEMING TP: Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin. Exp. Metastasis (2000) 18:391-400.
141. KAJIYAMA H, KIKKAWA F, SUZUKI T, SHIBATA K, INO K, MIZUTANI S: Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. (2002) 62:2753-2757.
142. SATO Y, FUJIWARA H, HIGUCHI T et al.: Involvement of Dipeptidyl Peptidase IV in Extravillous Trophoblast Invasion and Diffcrendation.J. Clin. Endocrinol. Metab. (2002) 87:4287-4296.
143. GHERSI G, DONG H, GOLDSTEIN LA et al.: Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J. Biol. Chem. (2002) 277(32):29231-29241.
144. STEINBRECHER A, REINHOLD D, QUIGLEY L et al.: Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and upregulates TGF-beta 1 secretion in vivo. J. Immunol. (2001) 166:2041-2048.
145. SHINOSAKI T, KOBAYASHI T, KIMURA K, KURIHARA H: Involvement of dipeptidyl peptidase TV in immune complex-mediated glomerulonephritis. Lab. Invest. (2002) 82:505-513.
146. GROUZMANN E, MONOD M, LANDIS B et al.: Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J. (2002) 16:1132-1134.
147. SEDO A, MALIK R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim. Biophys. Acta (2001) 1550:107-116.
148. HOLST JJ, DEACON CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes. Diabetes (1998) 47:1663-1670.
149. DEACON CF, HOLST JJ: Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of Type 2 diabetes: a historical perspective. Biochem. Biophys. Res. Commun. (2002) 294:1-4.
150. DEMUTH HU, HINKE SA, PEDERSON RA, MCINTOSH CH: Rebuttal to Deacon and Holst: 'Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1' versus 'Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of Type 2 diabetes: a historical perspective. Biochem. Biophys. Res. Commun. (2002) 296:229-232.
151. DEACON CF, HUGHES TE, HOLST JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes (1998) 47:764-769.
152. PEDERSON RA, WHITE HA, SCHLENZIG D, PAULY RP, MCINTOSH CH, DEMUTH HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47:1253-1258.
153. AHREN B, HOLST JJ, MARTENSSON H, BALKAN B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol (2000) 404:239-245.
154. DEACON CF, DANIELSEN P, KLARSKOV L, OLESEN M, HOIST JJ: Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes (2001) 50:1588-1597.
155. POSPISILIK JA, STAFFORD SG, DEMUTH HU et al.: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51:943-950.
156. POSPISILIK JA, STAFFORD SG, DEMUTH HU, MCINTOSH CH, PEDERSON RA: Long-term treatment with dipeptidyl peptidase iv inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes (2002) 51:2677-2683.
157. SUDRE B, BROQUA P, WHITE RB et al.: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes (2002) 51:1461-1469.
158. AHREN B, SIMONSSON E, LARSSON H et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in Type 2 diabetes. Diabetes Care (2002) 25:869-875.
159. HOFFMANN T, GLUND K, MCINTOSH CHS et al.:. DPPIV inhibition as treatment of type II diabetes. In: Cell-Surface Aminopeptidases. Basic and Clinical Aspects. S Mizutani (Ed.), Elsevier (2001):381-387.